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Brief Definit ive Report
After infection or injury, the immediate host 
inflammatory response is mediated by receptors 
on innate immune cells that can efficiently recog-
nize pathogen- or damage-associated molecular 
patterns (PAMPs or DAMPs). For instance, the 
mammalian response to bacterial endotoxin (LPS) 
is mediated by the LPS-binding protein (LBP), 
CD14, MD-2, and TLR4. Upon capturing LPS, 
LBP transfers it to CD14 and MD-2, which 
then delivers LPS to the signaling, high-affinity 
transmembrane receptor TLR4 (Nagai et al., 
2002). The engagement of LPS with TLR4 trig-
gers the sequential release of “early” (e.g., TNF, 
IL-1, and IFN-) and “late” proinflammatory 
mediators (e.g., HMGB1; Wang et al., 1999).
As a ubiquitous nuclear protein, HMGB1 can 
be passively released from damaged cells (Scaffidi 
et al., 2002) after sterile tissue injury as a result 
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Innate immune receptors for pathogen- and damage-associated molecular patterns (PAMPs 
and DAMPs) orchestrate inflammatory responses to infection and injury. Secreted by acti-
vated immune cells or passively released by damaged cells, HMGB1 is subjected to redox 
modification that distinctly influences its extracellular functions. Previously, it was un-
known how the TLR4 signalosome distinguished between HMGB1 isoforms. Here we demon-
strate that the extracellular TLR4 adaptor, myeloid differentiation factor 2 (MD-2), binds 
specifically to the cytokine-inducing disulfide isoform of HMGB1, to the exclusion of other 
isoforms. Using MD-2–deficient mice, as well as MD-2 silencing in macrophages, we show 
a requirement for HMGB1-dependent TLR4 signaling. By screening HMGB1 peptide librar-
ies, we identified a tetramer (FSSE, designated P779) as a specific MD-2 antagonist 
preventing MD-2–HMGB1 interaction and TLR4 signaling. P779 does not interfere with 
lipopolysaccharide-induced cytokine/chemokine production, thus preserving PAMP-mediated 
TLR4–MD-2 responses. Furthermore, P779 can protect mice against hepatic ischemia/
reperfusion injury, chemical toxicity, and sepsis. These findings reveal a novel mechanism by 
which innate systems selectively recognize specific HMGB1 isoforms. The results may direct 
toward strategies aimed at attenuating DAMP-mediated inflammation while preserving 
antimicrobial immune responsiveness.
© 2015 Yang et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Cys106 (disulfide HMGB1), activates immune cells to produce 
cytokines/chemokines via the TLR4 receptor. Once all cyste-
ines are terminally oxidized (sulfonyl HMGB1), HMGB1 is 
devoid of chemotactic and cytokine activities (Tang et al., 2012; 
Venereau et al., 2012). Previously we showed that HMGB1 
induces inflammatory responses via the TLR4–MD-2 signal-
ing pathway and that the interaction with TLR4–MD-2 re-
quires a specific HMGB1 redox form with a distinct atomic 
structure of thiol-cysteine 106 (Yang et al., 2012). Ample evi-
dence suggests that HMGB1, when actively secreted by acti-
vated immune cells or passively released from dying cells, is a 
mixture of several isoforms with distinct posttranslational 
modifications (Yang et al., 2013). Paradoxically, it is unknown 
how the immune system uses the TLR4–MD-2 receptor 
system to distinguish between different isoforms of HMGB1, 
specifically recognizing the disulfide HMGB1 molecule to 
the exclusion of other isoforms.
MD-2 carries a hydrophobic pocket folded by two anti-
parallel -sheets for binding LPS (Park et al., 2009) and confers 
molecular specificity for LPS interaction and TLR4 signaling 
(Nagai et al., 2002; Meng et al., 2010). Accordingly, here we 
reasoned that MD-2 may similarly discriminate different 
HMGB1 isoforms to facilitate TLR4-dependent signaling. 
of ischemia/reperfusion (I/R; Tsung et al., 2005) or chemical 
toxicity (Antoine et al., 2013). HMGB1 can signal through a 
family of receptors, including RAGE (Huttunen et al., 1999), 
TLR4 (Yang et al., 2010), and cluster of differentiation 24 
(CD24)/Siglec-10 (Chen et al., 2009), thereby functioning as 
a DAMP that alerts, recruits, and activates innate immune 
cells to produce a wide range of cytokines and chemokines. 
Thus, seemingly unrelated conditions such as infection and 
sterile injury can converge on a common process: inflamma-
tion, which is orchestrated by HMGB1 actively secreted from 
innate immune cells or passively released from damaged tis-
sues (Zhang et al., 2010; Andersson and Tracey, 2011). Extra-
cellular HMGB1 has been established as a pathogenic mediator 
of both infection- and injury-elicited inflammatory diseases 
(Yang et al., 2013).
HMGB1 is a redox-sensitive protein as it contains three 
conserved cysteine residues at position 23, 45, and 106. The 
redox status of the cysteines dictates its extracellular chemokine- 
or cytokine-inducing properties. Specifically, HMGB1 with 
all cysteine residues reduced (fully reduced HMGB1) binds 
to CXCL12 and stimulates immune cell infiltration via the 
CXCR4 receptor in a synergistic fashion. Partially oxidized 
HMGB1, with a Cys23-Cys45 disulfide bond and a reduced 
Figure 1. Disulfide HMGB1 binds to MD-2. (A) TNF release was measured from RAW 264.7 cells stimulated with various isoforms of HMGB1 as  
indicated (1 µg/ml, 16 h). Data are presented as means ± SEM. *, P < 0.05 versus disulfide HMGB1. n = 3–5 experiments. (B) SPR (Biacore) analysis was 
performed to assess HMGB1 binding to MD-2 or TLR4 (coated on the chip). (top) HMGB1 binding to human MD-2 was tested at different HMGB1 con-
centrations (12.5, 25, 50, and 100 nM) with an apparent Kd of 12 nM (left). Human MD-2 (12.5, 25, 50, and 100 nM) binding to HMGB1 (coated on the 
chip; middle) and disulfide HMGB1 (100 nM) binding to TLR4 (coated on the chip; right) were tested. (bottom) Noncytokine-inducing HMGB1 (C106A,  
Hg-HMGB1, 1 µM) was tested for binding to MD-2 (coated on the chip; left). HMGB1 isoforms were tested for binding to MD-2 (coated on the chip; 
right). Data are presented as response units or relative response units over time (seconds) and are representative of three experiments. (C) Mixture of 
CBP-tagged HMGB1 or CBP alone with supernatant of yeast Sf9 cells expressing MD-2 was immunoprecipitated with calmodulin beads (immunoprecipi-
tation [IP]), and immunoblotted (IB) with anti–human MD-2 or CBP antibodies. Recombinant MD-2 protein was included as positive control (right lane). 
Data shown are representative of three repeats. (D) SPR analysis of HMGB1 binding to human MD-2 (coated on the chip) was performed in the presence 
of anti-HMGB1 mAb (left) or irrelevant mouse IgG (right) as shown. Data are representative of three repeats.
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RESULTS AND DISCUSSION
Cytokine-inducing (disulfide) HMGB1  
effectively binds to MD-2
HMGB1 contains three redox-sensitive cysteine residues that 
are modified by redox reactions to produce multiple HMGB1 
isoforms that extracellularly express or lack chemokine or cy-
tokine activities. To elucidate the underlying molecular mecha-
nisms, we examined whether MD-2, an extracellular adaptor 
Our current findings reveal that only the disulfide HMGB1 
binds to MD-2, and this interaction is critically important for 
HMGB1-mediated cytokine/chemokine production and the 
development of subsequent tissue injury. Screening of HMGB1 
peptide libraries identified a tetramer (FSSE, P5779) as a spe-
cific MD-2–targeting antagonist that prevents HMGB1–MD-2 
interaction and cytokine induction, thereby protecting ani-
mals against liver I/R injury, chemical toxemia, and sepsis.
Figure 2. MD-2 is indispensable for HMGB1-dependent TLR4 signaling. (A, top) Knockdown of MD-2 (siRNA) was performed on RAW 264.7 
cells. MD-2 and NF-B levels (p65) were assessed by Western blotting. The level of NF-B (p65) protein was normalized relative to the level of  
-actin (ratio) by densitometry and expressed as the fold change over unstimulated cells. (bottom) HMGB1-induced TNF release from RAW 264.7 
cells with MD-2 knockdown (open bars) or control siRNA (closed bars). *, P < 0.05 versus control siRNA group. n = 4–5 experiments. (B, left) HMGB1 
(2 µg/ml) or ultrapure LPS (200 ng/ml) was used to stimulate primary peritoneal macrophages from WT or MD-2 KO mice for 16 h, and NF-B  
(p50 and p65) protein levels in nuclear extracts were assessed by Western blotting (top left). NF-B activation is expressed as of p50 or p65 relative 
to -actin and calculated as the fold change over unstimulated cells (bottom left). (right) Mouse macrophages were stimulated with HMGB1 and 
cytokine release was measured using mouse cytokine antibody array (G-CSF, IL-12p40, IL-6, TNF, RANTES, MCP-1, and sTNFR1; top right) or ELISA 
(for TNF; bottom right). *, P < 0.05 versus WT group. n = 5 separate experiments. (C, left) WT or MD-2 KO mice were challenged with APAP in a liver  
injury model and were euthanized 24 h later to measure serum levels of liver enzymes (GLDH, ALT, and AST; left column of graphs) and cytokines 
(HMGB1, TNF, and IL-6; right column of graphs). *, P < 0.05 versus WT APAP group. n = 5–13 mice per group. (middle) Representative H&E staining 
of liver tissues from these mice are shown. n = 5–8 mice per group (the arrow indicates necrosis region). Bars, 100 µm. (right) Animal survival after 
receiving a lethal dose of APAP in WT and MD-2 KO mice was assessed (percent survival). *, P < 0.05 versus WT. n = 15 mice per group. (A–C) Data 
are presented as means ± SEM.
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thiol-cysteine 106 in the regulation of HMGB1 cytokine ac-
tivity (Fig. 1, A and B).
To further study HMGB1–MD-2 interactions, immuno-
precipitation assays were used to pull down MD-2 from HMGB1-
expressing cell lysates. Co-incubation with calmodulin-binding 
protein (CBP)–tagged disulfide HMGB1, but not CBP tag 
alone, pulled down MD-2 protein from yeast cells transfected 
with an MD-2–expressing construct (Fig. 1 C), confirming 
that MD-2 binds disulfide HMGB1. Furthermore, this inter-
action was blocked by anti-HMGB1 mAbs, but not by irrele-
vant IgG, demonstrating that the HMGB1–MD-2 interaction 
is specific and targetable by antagonists (Fig. 1 D).
MD-2 is required for HMGB1-mediated  
inflammatory responses
To further assess the importance of MD-2 in HMGB1-mediated 
cytokine induction, we used siRNA to knock down MD-2 
expression in murine macrophage-like RAW 264.7 cells or 
human (THP-1) monocytes. The silencing of MD-2 expres-
sion (by 80–90%) was accompanied by a significant reduction 
of HMGB1-stimulated NF-B activation and TNF release in 
both murine macrophages and human monocytes (Fig. 2 A 
and not depicted). To confirm the requirement for MD-2 in 
HMGB1-induced innate immune activation, thioglycollate-
elicited peritoneal macrophages were isolated from WT and 
MD-2 KO mice and stimulated by disulfide HMGB1. Dis-
ruption of MD-2 expression resulted in complete impair-
ment of both LPS- and HMGB1-induced activation of NF- 
B and secretion of cytokines (TNF and IL-6) and chemokines 
(e.g., RANTES and MCP-1; Fig. 2 B). The release of IL-12/p40 
stimulated with HMGB1 is via an MD-2–independent mech-
anism, likely attributable to signaling via other receptors.
HMGB1 is an important mediator of acetaminophen 
(APAP)-induced hepatotoxicity (Antoine et al., 2012). To eval-
uate the in vivo importance of MD-2 in HMGB1-induced 
inflammatory responses, we studied the impact of MD-2 de-
ficiency on sterile inflammation using the APAP intoxication 
model. The disruption of MD-2 expression resulted in a signif-
icant reduction in acute hepatic injury, as assessed by liver 
enzyme release (glutamate dehydrogenase [GLDH], aspartate 
aminotransferase [AST], and alanine aminotransferase [ALT]) 
and histological analysis of liver necrotic lesions compared with 
WT mice subjected to APAP injection (Fig. 2 C, arrow). Further-
more, the lessened hepatic damage in MD-2 KO mice was 
accompanied by significant reduction in cytokine (TNF and 
IL-6) release and APAP-induced animal lethality, confirming 
an essential role for MD-2 in sterile inflammation and injury 
(Fig. 2 C). Notably, serum HMGB1 levels were comparably 
elevated in WT and MD-2 KO mice at 24 h after APAP admin-
istration (Fig. 2 C). The central role of HMGB1 in APAP-induced 
liver toxicity was further confirmed by using an HMGB1-
neutralizing mAb, which significantly inhibited APAP- 
induced release of hepatic enzymes (ALT) and proinflammatory 
cytokines (TNF and IL-6) and improved survival (Fig. 3). 
Collectively, these in vivo experimental data reveal an essential 
role for MD-2 and HMGB1 in the pathogenesis of sterile injury.
receptor of the TLR4 signalosome, can discriminate various 
HMGB1 isoforms with their distinct inflammatory properties. 
Different forms of HMGB1, produced by point mutations or 
chemical modifications by exposure to mercury thiolates or 
the reducing agent dithiothreitol, were tested for their MD-2–
binding properties. Consistent with previous studies (Venereau 
et al., 2012; Yang et al., 2012), only the disulfide HMGB1 iso-
form induced TNF secretion (Fig. 1 A). Biosensor-based sur-
face plasmon resonance (SPR) analysis (Biacore) confirmed 
that only the disulfide HMGB1 binds to MD-2 with high af-
finity (apparent Kd = 12 nM) regardless of whether MD-2 or 
HMGB1 was immobilized on the sensor chip (Fig. 1 B). In 
contrast, HMGB1 was incapable of directly binding to TLR4 
(Fig. 1 B) in the absence of MD-2, although TLR4 was func-
tionally active in MD-2 binding in Biacore analysis (not de-
picted), implicating MD-2 as an essential participant in the 
HMGB1–TLR4 signaling pathway. Unlike the disulfide iso-
form of HMGB1, H2S modified, fully reduced, or sulfonyl 
HMGB1 failed to induce TNF release from macrophage 
cultures (Fig. 1 A), with >1,000-fold reduction in MD-2 
binding as compared with disulfide HMGB1 (Fig. 1 B). 
Notably, chemical modification of the cysteine 106 of the 
disulfide HMGB1 also abolished the TNF-stimulating and 
MD-2–binding properties, indicating a critical role of the 
Figure 3. Anti-HMGB1 mAb administration ameliorates APAP-
induced liver injury in mice. (A) Mice received an APAP injection (i.p.) 
followed by treatment with an anti-HMGB1 antibody or control IgG injec-
tion (i.p.; see Materials and methods). Animal survival (percent survival) 
was assessed. n = 20 mice/group. *, P < 0.05 versus IgG group. (B) Serum 
levels of liver enzyme (ALT) and cytokines (TNF and IL-6) at 24 h after 
APAP were measured in mice receiving treatment of anti-HMGB1 anti-
body or control IgG (see Materials and methods). *, P < 0.05 versus IgG 
group. n = 10 mice/group. (A and B) Data are presented as means ± SEM.
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To evaluate the therapeutic potential of the MD-2–binding 
peptide, we next studied whether P5779 was capable of 
disrupting MD-2–HMGB1 interactions, thereby inhibiting 
HMGB1-induced cytokine production. P5779 inhibited the 
MD-2–HMGB1 interaction in a concentration-dependent 
manner when either MD-2 or HMGB1 was coated onto the 
Biacore sensor chip (Fig. 5 A). Furthermore, P5779 inhibited 
HMGB1-induced TNF release in primary human macro-
phages in a concentration-dependent fashion (Fig. 5 B). The 
effective concentration of P5779 that suppressed 50% TNF 
release (IC50) was 5 µg/ml in the presence of HMGB1 at 
1 µg/ml. Scrambling the amino acid sequence of P5779 abol-
ished the capacity to inhibit HMGB1-induced TNF release 
(Fig. 5 B). Exposure of macrophages to P5779 failed to inhibit 
TNF release mediated by polyinosinic-polycytidylic acid 
(Poly I:C), S100A12, LPS, peptidoglycan (PGN), and CpG 
DNA (Fig. 5 B). P5779 also significantly reduced HMGB1-
induced release of other cytokines including IL-6 and IL-
12p40/p70 and chemokines such as RANTES and MCP-1 
(Fig. 5 C). P5779 did not inhibit LPS-stimulated cytokine/
chemokine release in vitro in macrophages (Fig. 5 D) and 
failed to attenuate LPS-induced systemic cytokine levels 
in vivo, even when administered at high doses (8 mg/kg) in 
mice (Fig. 5 E). Thus, P5779 selectively attenuates HMGB1–
MD-2–TLR4 signaling without inhibiting macrophage acti-
vation in response to PAMPs.
Development of a novel MD-2–binding peptide  
as an HMGB1-specific inhibitor
Having identified a critical involvement of the cysteine 106 re-
gion of HMGB1 in HMGB1–MD-2 interaction and HMGB1– 
TLR4 signaling, we used a rational strategy to screen for 
mimetic peptide inhibitors. A series of trimer and tetramer 
peptides spanning the cysteine 106 region and incorporating 
cysteine homologues were screened for MD-2–binding prop-
erties using the Biacore technology and molecular docking 
technique (Fig. 4, A, C, and D). Although most peptides lacked 
MD-2–binding capacity, we identified one epitope within 
the HMGB1 B box domain that acted as a potent HMGB1-
specific inhibitor. Molecular docking simulation revealed 
that the FSSE (P5779) tetramer fully extended into the hy-
drophobic pocket of MD-2, thereby forming maximal van der 
Waals interaction with surrounding hydrophobic residues 
along with an additional hydrogen bond with the Tyr102  
(Fig. 4 D). Consequently, it bound to MD-2 with a Kd value 
of 0.65 µM and significantly inhibited HMGB1-induced 
TNF release from human macrophages (Fig. 4, A and B). This 
interaction was specific, as P5779 failed to bind to other pro-
teins such as HMGB1 and TLR4 in the absence of MD-2 
(Fig. 4 C). Similarly, scrambling the amino acid sequence of 
P5779 (control peptide) abolished the MD-2–binding capac-
ity in Biacore experiments (Fig. 4 C) and in molecular dock-
ing analysis (Fig. 4 D).
Figure 4. Screening for HMGB1 inhibitors. (A) SPR analy-
sis was performed to test the interaction of MD-2 (coated on 
the chip) with P5779 (FSSE) and other peptides (100 nM).  
Kd values are shown. Data are representative of three experi-
ments. (B) Primary human macrophages were stimulated  
in vitro with HMGB1 (1 µg/ml) plus different peptides (50 µg/ml) 
for 16 h, and TNF release was measured by ELISA. Data are pre-
sented as means ± SEM. *, P < 0.05 versus HMGB1 alone. n = 4–5 
experiments. (C) SPR analysis was performed to measure bind-
ing of P5779 (12.5, 25, 50, and 100 nM) or scrambled control 
(ctrl) peptide (100 nM) to human MD-2 (Kd = 0.65 µM for 
P5779), HMGB1, or TLR4 (coated on the chip). Data are repre-
sentative of three experiments. (D) Schematic illustration 
showing molecular docking of MD-2 with tetramer peptides 
FSSE (left) and SFSE (right). The pink area represents the sur-
face of the peptide-binding pocket of MD-2, and the green 
area denotes the TLR4 protein surface. The bottom panel shows 
hydrogen bonds and van der Waals interactions. P5779, with  
a stronger van der Waals interaction than control, is fully ex-
tended into the hydrophobic pocket of MD-2 and forms an 
additional hydrogen bond with Tyr102 of MD-2.
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consistent with the known delayed pathogenic role of HMGB1 
in sepsis sequelae. Collectively, these results indicate that P5779 
disrupts binding of disulfide HMGB1 to MD-2, thereby atten-
uating HMGB1-mediated organ failure and mortality in vivo.
These results reveal a novel mechanism of selective innate 
immune cell recognition of HMGB1 by MD-2 that discrimi-
nates the HMGB1 isoforms. By screening HMGB1 peptide 
libraries, we identified a novel tetramer peptide (FSSE, P5779) 
that specifically prevents the MD-2–HMGB1 interaction 
without impairing the MD-2/LPS/TLR4 signaling in innate 
immune cells. This peptide conferred protection not only in 
animal models of sterile injury-elicited inflammatory diseases 
but also after a lethal infection challenge, opening the possi-
bility of developing novel therapeutic strategies to attenuate 
Therapeutic efficacy of MD-2–targeted P779  
in APAP toxicity, ischemia, and sepsis
In the APAP-induced liver toxicity model, P5779 treatment 
dose-dependently reduced APAP-induced elevation of he-
patic serum enzymes (AST and ALT), proinflammatory cyto-
kines (TNF), liver necrosis, and improved survival (Fig. 6 A, 
arrow). In sterile injury mediated by hepatic I/R, P5779 also 
significantly blunted hepatic serum enzyme release (AST and 
ALT) and neutrophil infiltration (Fig. 6 B, arrow). In addition, 
treatment with P5779 in a sepsis model induced by cecal liga-
tion and puncture (CLP) significantly and dose-dependently 
improved survival rates as compared with scrambled peptide-
treated controls (Fig. 6 C). Importantly, P5779 was effective 
even when administered 24 h after onset of the peritonitis, 
Figure . Development of a tetramer peptide (P779) as an MD-2–binding HMGB1-specific inhibitor. (A) On SPR analysis, HMGB1 was coated 
on the chip and MD-2 (1 µM) was flowed over as analyte, plus different amounts of P5779 as shown. Inhibition of HMGB1 binding to MD-2 by P5779 
(IC50 = 29 nM) was assessed (top). In the reverse experiment, human MD-2 was coated on the chip, and HMGB1 (1 µM) plus different amounts of P5779 
were added as analytes. HMGB1 binding to MD-2 was inhibited by P5779 (IC50 = 2 nM; bottom). Data are representative of three separate experiments. 
(B) Human primary macrophages, isolated from human blood, were stimulated with HMGB1 (1 µg/ml) or other stimuli (Poly I:C, S100A12, LPS, PGN, and 
CpG DNA) in vitro, plus increasing amounts of P5779 (or scrambled control peptide) for 16 h. TNF release was measured by ELISA. *, P < 0.05 versus 
HMGB1 plus control peptide (ctrl). n = 4–5 experiments. (C) Thioglycollate-elicited peritoneal mouse macrophages were stimulated in vitro with HMGB1 
(1 µg/ml) plus P5779 or control peptide (50 µg/ml) for 16 h, and extracellular levels of various cytokines were analyzed by mouse cytokine antibody array 
(left). Data are representative of three to four experiments, each performed in duplicate and expressed as fold increase over unstimulated cells using den-
sitometry (-HMGB1; right table). *, P < 0.05 versus +HMGB1 group. (D) Primary human macrophages, isolated from blood, were stimulated in vitro with 
LPS (2 ng/ml) for 16 h in the absence or presence of P5779 (50 µg/ml) or control peptide, and extracellular levels of various cytokines were analyzed by 
human cytokine antibody array. Data are representative of three repeats. (E) Male C57BL/6 mice received an LPS injection (8 mg/kg, i.p.) plus P5779 or 
control peptide (500 µg/mouse, i.p.). Animals were euthanized 90 min later. Serum TNF and IL-6 levels were measured by ELISAs. n = 5 mice per group. 
(B and E) Data are presented as means ± SEM.
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recent observations that HMGB1 levels are persistently ele-
vated during later stages of sepsis, despite termination of the 
initial infection, and contribute to long-term pathological 
consequences of sepsis (Valdés-Ferrer et al., 2013). Microbial-
induced sepsis can be clinically indistinguishable from the 
sterile injury-elicited systemic inflammatory response syn-
drome (SIRS; Sursal et al., 2013). Based on the findings that 
TLR4–MD-2 acts as a mutually exclusive signaling receptor 
complex for disulfide HMGB1, it is possible to develop strat-
egies that selectively attenuate DAMP-mediated inflamma-
tory responses while preserving PAMP-mediated signaling.
Substantial evidence supports the necessity to preserve early 
PAMP-mediated innate immune responses to counteract 
microbial infections. For instance, defective TLR4 signaling in 
C3H/HeJ mice is associated with aggravated disease severity and 
increased mortality in animal models of infection (Khanolkar 
et al., 2009). LPS enhances macrophage phagocytic activity 
DAMP-mediated injurious inflammatory responses without 
inhibiting PAMP-elicited innate immunity.
MD-2 carries a -cup fold structure composed of two 
antiparallel -sheets that form a large hydrophobic pocket for 
binding to LPS (Park et al., 2009). The estimated affinity of 
MD-2 binding to HMGB1 (12 nM) is comparable with MD-
2 binding to LPS (65 nM; Visintin et al., 2006). Further struc-
tural analysis is required to reveal the disulfide HMGB1-binding 
site on MD-2.
HMGB1-neutralizing antibodies are protective against ster-
ile injury (Tsung et al., 2005), and agents capable of inhibiting 
HMGB1 release or its extracellular activities (Wang et al., 
1999; Yang et al., 2004) also confer protection against sepsis. 
During early stages of sepsis, PAMP-mediated inflammatory 
responses are essential to host defense. At later stages, the re-
lease of DAMPs amplifies the cytokine storm and organ dys-
function (Wang et al., 2014). This notion is supported by 
Figure . Treatment with the HMGB1 inhibitor P779 ameliorates APAP-mediated toxicity, I/R injury, and sepsis mortality in vivo. (A, top left) 
C57BL/6 mice received an APAP injection (i.p.; see Materials and methods) and were administered with P5779 (at doses indicated) or control peptide (ctrl;  
500 µg/mouse, i.p.). Mice were euthanized at 24 h after APAP, and serum enzyme (ASL and ALT) and cytokine (TNF) levels were measured by ELISAs. n = 6–10 
mice per group. (bottom left) In survival experiments, mice received an APAP injection (i.p.) and were administered with P5779 or control peptide (i.p.; see 
Materials and methods). Survival was monitored for 2 wk (percent survival). n = 30 mice/group. (right) Representative H&E images of liver tissue sections are 
shown for normal (untreated) or APAP-injected mice receiving P5779 or control peptides. Clinical scores were assessed and are shown on the right. Liver 
necrosis is demonstrated by an arrow. n = 6–10 mice/group. *, P < 0.05 versus control peptide group. (B, left) P5779 or control peptide was administered  
(500 µg/mouse, i.p.) at the time of I/R surgery, and mice were euthanized 6 h later to measure serum levels of ALT and AST and to evaluate histological liver 
injury. *, P < 0.05 versus I/R group. n = 5–7 mice/group. (right) Representative H&E liver tissue sections are shown (neutrophil infiltration: arrow). n = 3–5 
mice per group. (A and B) Data are presented as means ± SEM. Bars, 100 µm. (C) Mice received CLP surgery, and P5779 or control peptide was administered 
i.p. at the doses indicated. Animal survival was monitored for 2 wk (percent survival). *, P < 0.05 versus control peptide group. n = 20 mice/group.
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50 µg/ml, and TLR9 agonist CpG DNA at 1 µM, plus increasing amounts of 
P5779 (or scrambled control peptide) as indicated for 16 h. TNF release was 
measured by ELISA.
Immunoprecipitation assay. Recombinant rat HMGB1 with a CBP tag 
or 10 µg CBP peptide alone was incubated overnight with 50 µl human 
MD-2 supernatant (precleared with calmodulin beads) at 4°C with gentle 
shaking. Human MD-2 supernatant was obtained from sf9 insect cells trans-
fected with human MD-2 (Teghanemt et al., 2008). Both HMGB1 and MD-2 
supernatant contained nondetectable amounts of LPS as measured by Limu-
lus amebocyte lysate assay. The mixture of CBP-HMGB1 or CBP and MD-2 
was then incubated with calmodulin beads (30 µl drained beads) for 1 h at 
4°C. After extensive washing with PBS containing 0.1% Triton X-100, pro-
teins bound to the beads were analyzed by Western blot probed with anti–
human MD-2 or anti-CBP antibodies.
Cytokine and NF-B measurements. Levels of TNF and IL-6 released 
in the cell culture or from mice serum were measured by ELISA kits (R&D 
Systems). Serum HMGB1 levels were measured by ELISA kit (IBL Interna-
tional). Cytokine expression profile from thioglycollate-elicited peritoneal 
macrophages of mice or primary human macrophages was determined by 
mouse or human cytokine array C1 (Raybiotech) according to the manufac-
turer’s instructions. 22 cytokines or chemokines were determined simultane-
ously. NF-B activation was analyzed by detecting p50 and p65 expression in 
the nuclear fraction by Western blot. -Actin expression was also measured as 
control for equal loading of samples. Western blots were scanned with a silver 
image scanner (Silver-scanner II; Lacie Limited), and the relative band in-
tensity was quantified using ImageJ software (v1.59; National Institutes of 
Health) and expressed as a ratio to the amount of -actin.
SPR analysis. The Biacore T200 instrument was used for real-time binding 
interaction experiments. For HMGB1–MD-2 binding analyses, human MD-2 
was immobilized onto a CM5 series chip (GE Healthcare). One flow cell was 
used as a reference and thus immediately blocked upon activation by 1 M etha-
nolamine, pH 8.5. The sample flow cell was injected with disulfide HMGB1 
(or isoforms; in 10 mM acetate buffer, pH 5.2) at a flow rate of 10 µl/min for 
7 min at 25°C. Increasing concentrations of disulfide HMGB1 or isoforms of 
HMGB1 (C106A, sulfonyl, fully reduced, Hg, or H2S-modified HMGB1 at 
1 µM) were flowed over immobilized MD-2. In reverse fashion, HMGB1 was 
coated on the chip and various amounts of MD-2 were added as analyte. Find-
ings were confirmed by using two additional human MD-2 proteins from D.
T. Golenbock and T.R. Billiar. For TLR4-HMGB1 binding experiments, 
human TLR4 was coated on the chip, and 100 nM disulfide HMGB1 was 
added as analyte. For peptide screening experiments, human MD-2 was coated 
on the sensor chip, trimer, or 100 nM tetramer peptides (FSSE, FSSEY, FEEE, 
FEED, SSE, and SFSE) were added as analytes. The dissociation time was set 
for 2 min, followed by a 1-min regeneration using a 10 mM NaOH solution. 
The Kd was evaluated using the Biacore evaluation software. For experiments 
using HMGB1 antibody to block MD-2–HMGB1 interaction, human MD-2 
was coated on the chip, HMGB1 was added as analyte (100 nM) plus increasing 
amounts of HMGB1 mAb or control IgG, and response units were recorded.
Molecular docking of MD-2 with peptides. The crystal structure of the 
MD-2–TLR4 was obtained from the Protein Data Bank (PDB code: 3VQ2), 
and molecular docking was performed by using the MOE software as previ-
ously described (Zan et al., 2012). A molecular visualization system, the 
PyMOL 0.99, was used to construct the three-dimensional figures.
Knockdown MD-2 in RAW 264.7 and THP-1 cells using siRNA. For 
MD-2 knockdown in RAW 264.7 cells, cells were transfected with mouse 
MD-2 or 50 nM control siRNA (on-target plus smart pool; GE Healthcare) 
using DharmaFect1 transfection reagent. To knock down MD-2 in THP-1 
cells, transfection with MD-2–specific siRNA was performed by using an 
Amaxa Nucleofector kit (Lonza). The efficiency of knockdown was confirmed 
by Western blot probed with anti–MD-2 antibody at 48 h after transfection. 
through TLR4, and selective deletion of TLR4 on myeloid cells 
impairs bacterial clearance in the CLP model (Deng et al., 
2013). These findings emphasize the importance of generating 
therapeutic approaches to selectively target damage-mediated 
inflammation while preserving physiological protective im-
mune responses. The discovery of P5779 as an MD-2–targeting 
selective inhibitor for the DAMP- but not the PAMP-elicited 
inflammatory responses provides such a novel therapeutic tool.
MATERIALS AND METHODS
Reagents. Human TLR4–MD-2 complex, human MD-2, TLR2, and solu-
ble RAGE were obtained from R&D Systems. LPS (Escherichia coli; 0111:B4), 
APAP, Triton X-114, PGN from Bacillus subtilis, blasticidin S, NaSH, mouse 
IgG, and human macrophage-CSF (M-CSF) were purchased from Sigma-
Aldrich. Protein A/G agarose and isopropyl-d-thiogalactopyranoside (IPTG) 
were from Thermo Fisher Scientific. NHS-activated Sepharose 4 fast flow 
beads were obtained from GE Healthcare. Thioglycollate medium was pur-
chased from BD. Ultrapure LPS, Poly I:C, and type B CpG oligonucleotide 
were obtained from InvivoGen. Human S100 A12 was from Circulex Co. 
Anti–human and –mouse MD-2 antibodies were obtained from Imgenex. 
Anti-CBP tag antibody was from GenScript. Anti-p50 antibody (E381) and anti-
p65 antibody were obtained from Epitomics and Santa Cruz Biotechnology, 
Inc., respectively. Serum ALT and AST levels were determined by color end-
point assay kits from BIOO Scientific.
Preparations of HMGB1 proteins, antibodies, and peptides. Recom-
binant HMGB1 was expressed in E. coli and purified to homogeneity as de-
scribed previously (Wang et al., 1999; Li et al., 2004). This cytokine-stimulating 
HMGB1 contains a disulfide bond between cysteines 23 and 45 and reduced 
thiol on cysteine 106, characterized by liquid chromatography tandem mass 
spectrometric analysis (LC-MS/MS; Yang et al., 2012). HMGB1 with redox 
modifications was created chemically by a synthetic formation of mercury 
thiolate on cysteine at position 106 (Hg-HMGB1), by S-sulfhydration (H2S) 
to convert cysteine thiol (-SH) group to -SSH or by mutation of cysteine 
106 to alanine (C106A HMGB1) as described previously (Yang et al., 2010, 
2012). HMGB1 with cysteine modified by H2S was generated by incubating 
HMGB1 with 5 mM NaSH for 3 h at room temperature. Oxidized or DTT-
reduced HMGB1 was prepared as previously described (Yang et al., 2012). 
The LPS content in HMGB1 was measured by the Chromogenic Limulus 
Amebocyte Lysate Assay (Lonza). HMGB1 was extracted with Triton X-114 
to remove any contaminating LPS as described previously (Li et al., 2004). 
The purity and integrity of all recombinant proteins were verified by Coo-
massie blue staining after SDS-PAGE, with a purity predominantly >85%. 
The LPS content in all HMGB1 protein preparations is undetectable or 
<10 pg/mg protein as measured by Limulus assay. Anti-HMGB1 mAb (2g7) 
was generated as reported previously (Qin et al., 2006). Trimer or tetramer 
peptides (FSSE, FSSEY, FEEE, FEED, SSE, and SFSE) and CBP (MKRRWK-
KNFIAVSAANRFKKISSSGAL) were all custom-made from GeneMed Inc. 
The peptides were purified to 90% purity as determined by HPLC. Endo-
toxin was not detectable in the synthetic peptide preparations as measured by 
Limulus assay. The peptides were first dissolved in DMSO and further diluted 
in PBS as instructed by the manufacturer and prepared freshly before use. 
Pre-casted mini-protean Tris-Tricine gels were from Bio-Rad Laboratories.
Cell isolation and culture. Thioglycollate-elicited peritoneal macrophages 
were obtained from mice (C57BL/6 or gene knockout, male, 10–12 wk old) 
injected with 2 ml of sterile 4% thioglycollate broth i.p. as previously de-
scribed (Yang et al., 2010). Murine macrophage-like RAW 264.7 and human 
leukemia monocytes THP-1 were obtained from ATCC. Human primary 
monocytes were purified by density gradient centrifugation through Ficoll 
from blood donated by normal individuals as reported previously (Yang et al., 
2010). Human primary macrophages in 96-well plates were stimulated with 
HMGB1 at 1 µg/ml, TLR4 agonist LPS at 4 ng/ml, TLR3 agonist Poly I:C 
at 50 µg/ml, TLR2 agonist PGN at 5 µg/ml, RAGE agonist S100A12 at 
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t test and one-way ANOVA followed by the least significant difference test. 
Differences between groups in animal survival experiments were determined 
using two-tailed Fisher’s exact test. Cytokine array experiments were analy-
zed using the software UN-Scan-it from Silk Scientific Inc. P-values <0.05 
were considered statistically significant.
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